Search research articles
Contact Us
Filters
Showing results (111-120 of 142) with videos related to
Page
of 15
Sort By:
Annals of Surgery
|
September 6, 2000
Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal study
F Michelassi, R D Hurst, M Melis, et al.
Alimentary Pharmacology & Therapeutics
|
September 1, 2005
Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine
M P Sparrow, S A Hande, S Friedman, et al.
Gastroenterology
|
May 1, 1993
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group
J W Singleton, S B Hanauer, G L Gitnick, et al.
Alimentary Pharmacology & Therapeutics
|
June 5, 2013
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease
W J Sandborn, D E Elliott, J Weinstock, et al.
Alimentary Pharmacology & Therapeutics
|
June 8, 2011
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease
M A Kamm, S B Hanauer, R Panaccione, et al.
Inflammatory Bowel Diseases
|
June 1, 2001
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study
B E Sands, W J Tremaine, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics
|
November 19, 2013
Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease
T Dassopoulos, M C Dubinsky, J L Bentsen, et al.
Gastroenterology
|
August 28, 1998
Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group
S B Hanauer, M Robinson, R Pruitt, et al.
Gastroenterology
|
December 13, 2000
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group
R N Fedorak, A Gangl, C O Elson, et al.
The New England Journal of Medicine
|
October 9, 1997
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
S R Targan, S B Hanauer, S J van Deventer, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 142) with videos related to
Sort By:
Page
of 15
Annals of Surgery
|
September 6, 2000
Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal study
F Michelassi, R D Hurst, M Melis, et al.
Alimentary Pharmacology & Therapeutics
|
September 1, 2005
Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine
M P Sparrow, S A Hande, S Friedman, et al.
Gastroenterology
|
May 1, 1993
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group
J W Singleton, S B Hanauer, G L Gitnick, et al.
Alimentary Pharmacology & Therapeutics
|
June 5, 2013
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease
W J Sandborn, D E Elliott, J Weinstock, et al.
Alimentary Pharmacology & Therapeutics
|
June 8, 2011
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease
M A Kamm, S B Hanauer, R Panaccione, et al.
Inflammatory Bowel Diseases
|
June 1, 2001
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study
B E Sands, W J Tremaine, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics
|
November 19, 2013
Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease
T Dassopoulos, M C Dubinsky, J L Bentsen, et al.
Gastroenterology
|
August 28, 1998
Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group
S B Hanauer, M Robinson, R Pruitt, et al.
Gastroenterology
|
December 13, 2000
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group
R N Fedorak, A Gangl, C O Elson, et al.
The New England Journal of Medicine
|
October 9, 1997
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
S R Targan, S B Hanauer, S J van Deventer, et al.
Page
of 15